Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis.
暂无分享,去创建一个
Aki Tsuchiya | John Brazier | Nick Bansback | Carlo Marra | J. Brazier | A. Tsuchiya | N. Bansback | A. Anis | C. Marra | D. Guh | Tony Hammond | Daphne Guh | Aslam Anis | Tony Hammond
[1] L. Klareskog,et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.
[2] J. Fries,et al. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. , 1982, The Journal of rheumatology.
[3] P. Lipsky,et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.
[4] B. Zheng. Summarizing the goodness of fit of generalized linear models for longitudinal data. , 2000, Statistics in medicine.
[5] M. Drummond,et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. , 2003, The Journal of rheumatology.
[6] D. Symmons,et al. Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry , 2008 .
[7] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[8] Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. , 2004, Rheumatology.
[9] D. Fryback,et al. Report of Nationally Representative Values for the Noninstitutionalized US Adult Population for 7 Health-Related Quality-of-Life Scores , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[10] Ross D Crosby,et al. Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[11] J. Ware. SF-36 health survey: Manual and interpretation guide , 2003 .
[12] A. Brennan,et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. , 2004, Rheumatology.
[13] P Wainwright,et al. Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations. , 2004, Health technology assessment.
[14] P. Tugwell,et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. , 1993, The Journal of rheumatology.
[15] D. Scott,et al. Quality of life measures: use and abuse. , 2000, Bailliere's best practice & research. Clinical rheumatology.
[16] R. Brooks. EuroQol: the current state of play. , 1996, Health policy.
[17] J. Brazier,et al. The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.
[18] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[19] J. Kopec,et al. A Comparison of Four Indirect Methods of Assessing Utility Values in Rheumatoid Arthritis , 2004, Medical care.
[20] P Barton,et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. , 2004, Health technology assessment.
[21] Andrew Booth,et al. A Review of the Use of Health Status Measures in Economic Evaluation , 1999, Journal of health services research & policy.
[22] P. Dolan,et al. Modeling valuations for EuroQol health states. , 1997, Medical care.
[23] J. Brazier,et al. A comparison of the EQ-5D and SF-6D across seven patient groups. , 2004, Health economics.
[24] J. Brazier,et al. Deriving preference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ5D indices , 2002 .
[25] J. Wong. Cost-effectiveness of anti-tumor necrosis factor agents. , 2004, Clinical and experimental rheumatology.
[26] A. Silman,et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.